Intake of dietary copper helps Alzheimer's patients

October 03, 2005

As one of the services for patients with Alzheimer's disease, the Department of Psychiatry at the Saarland University Medical Center offers participation in a clinical phase II trial. This clinical trial aims to elucidate a potential beneficial effect of copper orotate (an organic copper salt), which is given together with a standard cholinesterase inhibitor. A diagnosis of mild to moderate dementia of the Alzheimer type is a prerequisite. Besides clinical investigations, laboratory investigations of blood and cerebrospinal fluid, and magnet resonance imaging of the brain will be carried out. The study is being conducted by Professor Dr. Thomas Bayer, the Head of the Division of Neurobiology, and Dr. Frank Pajonk, a Psychiatrist, at the Department of Psychiatry, Saarland University Medical Center.

Treatment starts after all prerequisites to participate have been met. Half of the patients receive 8 mg copper orotate per day, the other half a placebo. Both patients and psychiatrists are blinded. During the 12-month long double-blind phase, there will be extensive laboratory, clinical and neuropsychological tests. After the double-blind phase, we offer an open-label phase for all patients. At present, 15 patients have finished the double-blind phase. The copper medication is well tolerated.

Alzheimer is characterized by the presence of amyloid plaques, which are composed primarily of Aß peptide. Aß is produced within neurons and is liberated from the larger amyloid ß protein precursor (AßPP). Lower levels of copper have been reported in the brain of AßPP transgenic mice and post-mortem in AD patients. This concept has been found to be true also in vitro by Professor Dr. Gerd Multhaup (FU Berlin) in 1999. Two recent papers, which have been published in PNAS in 2003 have proven a beneficial effect of elevated copper in transgenic AßPP mice. In the present study, the teams led by Bayer and Multhaup have found that low copper level in blood correlates with advanced memory deficits, as tested by the well established ADAS-cog neuropsychological test battery. Patients with higher blood copper levels make fewer mistakes in this memory test. This result supports the notion of a mild copper deficiency in AD patients. An increased uptake of dietary copper may therefore be therapeutically relevant.
-end-
The study has been published in the September 2005 issue of the Journal of Alzheimer's Disease, Volume 8, Issue 1 published by IOS Press: "Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease" (JAD, Vol. 8, Issue 1).

About the Journal of Alzheimer's Disease

The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer's disease.

About IOS Press

Commencing its publishing activities in 1987, IOS Press (www.iospress.com) is a rapidly expanding scientific, technical, medical and professional publishing house focusing on a broad range of subject areas. Headquartered in Amsterdam, IOS Press publishes approximately 100 new books per annum and 70 international journals, covering topics ranging from computer science and mathematics to medicine and the natural sciences. Electronic access to all journals is now available. IOS Press also maintains offices in the Washington, DC area and Berlin and a co-publishing relationship with Ohmsha, Ltd (Tokyo).

Case Western Reserve University

Related Copper Articles from Brightsurf:

New material 'mines' copper from toxic wastewater
A team of scientists led by Berkeley Lab has designed a new material -- called ZIOS (zinc imidazole salicylaldoxime) -- that targets and traps copper ions from wastewater with unprecedented precision and speed.

Team uses copper to image Alzheimer's aggregates in the brain
A proof-of-concept study conducted in a mouse model of Alzheimer's disease offers new evidence that copper isotopes can be used to detect the amyloid-beta protein deposits that form in the brains of people living with -- or at risk of developing -- Alzheimer's.

Copper boosts pig growth, and now we know why
Pigs have better feed conversion rates with copper in their diets, but until now, scientists didn't fully understand why.

Cancer cells spread using a copper-binding protein
Researchers at Chalmers University of Technology, Sweden, have shown that the Atox1 protein, found in breast cancer cells, participates in the process by which cancer cells metastasise.

Adding copper strengthens 3D-printed titanium
Successful trials of titanium-copper alloys for 3D printing could kickstart a new range of high-performance alloys for medical device, defence and aerospace applications.

Matrix could ensure vital copper supplies
Researchers have identified a matrix of risks that the mining industry must overcome to unlock vitally important copper reserves.

Do microbes control the formation of giant copper deposits?
One of the major issues when studying ore deposits formed in surficial or near-surface environments is the relationship between ore-forming processes and bacteria.

Copper compound as promising quantum computing unit
Chemists at Friedrich Schiller University in Jena (Germany) have now synthesised a molecule that can perform the function of a computing unit in a quantum computer.

Copper ions flow like liquid through crystalline structures
Materials scientists have sussed out the physical phenomenon underlying the promising electrical properties of a class of materials called superionic crystals through the investigation of CuCrSe2.

A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.

Read More: Copper News and Copper Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.